PCV81 AN ECONOMIC EVALUATION OF THE ADDITION OF FIXED-DOSE NIACIN EXTENDED-RELEASE AND SIMVASTATIN THERAPY TO THE MANAGED CARE FORMULARY IN TERMS OF OPTIMAL LIPID VALUE ATTAINMENT
Nov 1, 2008, 00:00 AM
10.1016/S1098-3015(10)66379-6
https://www.valueinhealthjournal.com/article/S1098-3015(10)66379-6/fulltext
Section Title :
Section Order :
214
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)66379-6&doi=10.1016/S1098-3015(10)66379-6